# IFI6

## Overview
IFI6, or interferon alpha inducible protein 6, is a gene that encodes a protein involved in the regulation of apoptosis and immune responses. The protein, categorized as a type I interferon-stimulated protein, is primarily localized in the cytoplasm and associated with mitochondria, where it plays a crucial role in maintaining mitochondrial integrity and function. IFI6 exerts anti-apoptotic effects by inhibiting the release of cytochrome c from mitochondria, thereby delaying apoptosis through the TNF-related apoptosis-inducing ligand/caspase 8 pathway (Meyer2015Interferonα). Additionally, IFI6 modulates signaling pathways that influence cell proliferation and viral entry, such as the epidermal growth factor receptor (EGFR) pathway, which is significant in the context of viral infections like hepatitis C (Meyer2015Interferonα). The gene's expression and function have been implicated in various cancers, where it may serve as a prognostic marker and therapeutic target due to its role in tumor progression and treatment resistance (Gupta2016Interferon; VietNhi2024MultiOmics).

## Function
IFI6, or interferon alpha inducible protein 6, is a type I interferon-stimulated gene that plays a significant role in regulating apoptosis and immune responses. In healthy human cells, IFI6 is primarily active in the cytoplasm and is associated with mitochondria, where it influences mitochondrial function and integrity. It inhibits the release of cytochrome c from mitochondria, thereby delaying apoptosis initiated by the TNF-related apoptosis-inducing ligand/caspase 8 pathway (Meyer2015Interferonα). This anti-apoptotic function is crucial in various cellular contexts, including immune responses and potentially in cancer cells, where it can inhibit caspase 3 activation and suppress pro-apoptotic gene expression (Xu2021ATF3).

IFI6 also modulates signaling pathways involved in cell proliferation and viral entry processes. It impairs the activation of the epidermal growth factor receptor (EGFR) by CD81, which is crucial for the entry of certain viruses, such as the hepatitis C virus, into cells (Meyer2015Interferonα). This modulation of EGFR signaling can affect downstream pathways like the Ras/Raf/Erk signaling cascade, influencing cell proliferation and migration (Meyer2015Interferonα). Through these mechanisms, IFI6 contributes to the cellular defense against viral infections and may play a role in regulating cellular stress responses.

## Clinical Significance
Alterations in the expression of the IFI6 gene have been implicated in various cancers, including esophageal cancer (ESCA), ovarian cancer (OC), and NRAS-mutant melanoma. In esophageal cancer, higher expression levels of IFI6 are associated with poorer overall survival rates, advanced tumor stages, and increased risk of nodal metastasis. This suggests that IFI6 could serve as a prognostic indicator in ESCA (VietNhi2024MultiOmics). In ovarian cancer, IFI6 is linked to poor overall survival and resistance to chemotherapy drugs like cisplatin. Downregulation of IFI6 in OC cells reduces proliferation and increases sensitivity to cisplatin, indicating its potential as a therapeutic target (Zhao2021SingleCell).

In NRAS-mutant melanoma, IFI6 is necessary for oncogenic NRAS-induced transformation and tumor growth. Its upregulation confers resistance to DNA replication stress-inducing agents, but knockdown of IFI6 increases sensitivity to these agents, highlighting a potential therapeutic strategy (Gupta2016Interferon). These findings underscore the clinical significance of IFI6 in cancer progression and treatment resistance, suggesting it as a potential biomarker and therapeutic target across multiple cancer types.

## Interactions
IFI6, or interferon alpha inducible protein 6, is involved in various interactions with other proteins, particularly in the context of viral infections. In hepatitis C virus (HCV) infection, IFI6 does not directly interact with HCV structural proteins such as Core, E1, or E2, nor does it co-localize with CD81, a co-receptor involved in HCV entry. However, IFI6 impairs the co-localization of CD81 with claudin-1 (CLDN1), disrupting the interaction necessary for HCV entry into host cells (Meyer2015Interferonα). IFI6 also affects the epidermal growth factor receptor (EGFR) signaling pathway by inhibiting its activation when CD81 is cross-linked, which is crucial for HCV entry (Meyer2015Interferonα).

IFI6 interacts with the HCV protein p7, forming a complex that affects mitochondrial membrane potential. This interaction is part of the virus's strategy to evade the immune response by counteracting the antiviral effects of IFI6 (Qi2017Systematic). The p7 protein of HCV coimmunoprecipitates with IFI6-16, a variant of IFI6, suggesting a physical interaction that allows p7 to suppress the antiviral function of IFI6-16 by depolarizing mitochondrial potential (Qi2017Systematic).


## References


[1. (Zhao2021SingleCell) Hongyu Zhao, Zhefeng Li, Yan Gao, Jie Li, Xiaoting Zhao, and Wentao Yue. Single-cell rna-sequencing portraying functional diversity and clinical implications of ifi6 in ovarian cancer. Frontiers in Cell and Developmental Biology, August 2021. URL: http://dx.doi.org/10.3389/fcell.2021.677697, doi:10.3389/fcell.2021.677697. This article has 12 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fcell.2021.677697)

[2. (Xu2021ATF3) Lin Xu, Tingjian Zu, Tao Li, Min Li, Jun Mi, Fuxiang Bai, Guanyi Liu, Jie Wen, Hui Li, Cord Brakebusch, Xuxia Wang, and Xunwei Wu. Atf3 downmodulates its new targets ifi6 and ifi27 to suppress the growth and migration of tongue squamous cell carcinoma cells. PLOS Genetics, 17(2):e1009283, February 2021. URL: http://dx.doi.org/10.1371/journal.pgen.1009283, doi:10.1371/journal.pgen.1009283. This article has 18 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1371/journal.pgen.1009283)

[3. (Gupta2016Interferon) Romi Gupta, Matteo Forloni, Malik Bisserier, Shaillay Kumar Dogra, Qiaohong Yang, and Narendra Wajapeyee. Interferon alpha-inducible protein 6 regulates nrasq61k-induced melanomagenesis and growth. eLife, September 2016. URL: http://dx.doi.org/10.7554/elife.16432, doi:10.7554/elife.16432. This article has 21 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.7554/elife.16432)

[4. (VietNhi2024MultiOmics) Nguyen-Kieu Viet-Nhi, Tran Minh Quan, Vu Cong Truc, Tran Anh Bich, Pham Hoang Nam, Nguyen Quoc Khanh Le, Po-Yueh Chen, and Shih-Han Hung. Multi-omics analysis reveals the ifi6 gene as a prognostic indicator and therapeutic target in esophageal cancer. International Journal of Molecular Sciences, 25(5):2691, February 2024. URL: http://dx.doi.org/10.3390/ijms25052691, doi:10.3390/ijms25052691. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms25052691)

[5. (Qi2017Systematic) Hangfei Qi, Virginia Chu, Nicholas C. Wu, Zugen Chen, Shawna Truong, Gurpreet Brar, Sheng-Yao Su, Yushen Du, Vaithilingaraja Arumugaswami, C. Anders Olson, Shu-Hua Chen, Chung-Yen Lin, Ting-Ting Wu, and Ren Sun. Systematic identification of anti-interferon function on hepatitis c virus genome reveals p7 as an immune evasion protein. Proceedings of the National Academy of Sciences, 114(8):2018–2023, February 2017. URL: http://dx.doi.org/10.1073/pnas.1614623114, doi:10.1073/pnas.1614623114. This article has 30 citations.](https://doi.org/10.1073/pnas.1614623114)

[6. (Meyer2015Interferonα) Keith Meyer, Young-Chan Kwon, Shuanghu Liu, Curt H. Hagedorn, Ratna B. Ray, and Ranjit Ray. Interferon-α inducible protein 6 impairs egfr activation by cd81 and inhibits hepatitis c virus infection. Scientific Reports, March 2015. URL: http://dx.doi.org/10.1038/srep09012, doi:10.1038/srep09012. This article has 54 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/srep09012)